je.st
news
Tag: hepatitis
Enanta Announces 95 percent SVR12 Rate In AbbVie's Phase 3 Study Of All-Oral Treatment For Hepatitis C Virus In Japanese Patients
2015-02-04 07:01:33| drugdiscoveryonline Home Page
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, recently announced topline Phase 3 results from the GIFT-1 study, AbbVie’s investigational, all-oral, ribavirin-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan
Biz Break: Gilead hepatitis C drugs rack up more huge sales, cash headed to investors
2015-02-04 02:13:49| Biotech - Topix.net
Today: Gilead Sciences completes a transformational financial year with another huge quarter, thanks to sales of Foster City company's breakthrough hepatitis C medications, and will push that cash back to investors as discounts begin to take effect. Also: Twitter jumps amid changes.
Quest Diagnostics, CDC collaborate to reduce deaths from hepatitis
2015-01-29 04:10:24| Biotech - Topix.net
Quest Diagnostics , the world's leading provider of diagnostic information services, today announced that it will collaborate with the Centers for Disease Control and Prevention to identify trends in screening, diagnosis and treatment for four strains of viral hepatitis in the United States, based on insights revealed by analysis of Quest's national testing database. Under terms of the multi-year contract, Quest Diagnostics will provide CDC researchers with analytics expertise and access to the company's national Quest Diagnostics Health Trends database of de-identified clinical testing hepatitis data.
Tags: reduce
quest
deaths
diagnostics
UPDATE 2-UnitedHealth backs Gilead's Harvoni as preferred hepatitis C treatment
2015-01-29 03:19:07| Beverages - Topix.net
UnitedHealth Group Inc, the largest U.S. health insurer, on Wednesday backed Gilead Sciences Inc's Harvoni as the preferred hepatitis C treatment on its 2015 commercial drug coverage list, another victory for Gilead over competitor AbbVie Inc. Gilead and AbbVie have been battling for hepatitis C market share since the approval in December for an AbbVie drug that challenges Gilead's blockbusters. Insurers and pharmacy benefit managers have been striking deals for preferred or exclusive status in exchange for discounts for 2015.
Tags: update
treatment
preferred
backs
Gilead Expands Hepatitis C Generic Licensing Agreements to Include...
2015-01-26 12:49:40| Biotech - Topix.net
FOSTER CITY, Calif.-- -- Gilead Sciences, Inc. today announced that the company has expanded its hepatitis C generic licensing agreements to include the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C. The expanded agreements will allow Gilead's India-based partners to manufacture GS-5816 and the single tablet regimen of sofosbuvir/GS-5816, once approved, for distribution in 91 developing countries, which together account for 54 percent of the total worldwide population of individuals infected with the hepatitis C virus .
Tags: include
generic
licensing
agreements
Sites : [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] next »